Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Hutton

Showing results (21-30 of 103) with videos related to

Pageof 11
Sort By:
JAMA Ophthalmology|February 2, 2023
Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular EdemaDavid W Hutton, Adam R Glassman, Danni Liu, et al.
Annals of Internal Medicine|December 17, 2009
Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemicNayer Khazeni, David W Hutton, Alan M Garber, et al.
Vaccine|April 24, 2019
Are community health workers cost-effective for childhood vaccination in India?Deepti Bettampadi, Matthew L Boulton, Laura E Power, et al.
Annals of Internal Medicine|October 3, 2007
Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis BDavid W Hutton, Daniel Tan, Samuel K So, et al.
Gastroenterology|October 28, 2017
Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care ProvidersThilo Rattay, Ian P Dumont, Hauke S Heinzow, et al.
The American Journal of Gastroenterology|June 13, 2020
Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and HarmsNeehar D Parikh, Amit G Singal, David W Hutton, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 1, 2011
Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?Jeffrey K Belkora, David W Hutton, Dan H Moore, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|June 16, 2009
Are patients getting the "gist" in risk communication? Patient understanding of prognosis in breast cancer treatmentDavid W Hutton, Jeffrey K Belkora, Ross D Shachter, et al.
Plos One|June 23, 2016
Hitting the Optimal Vaccination Percentage and the Risks of Error: Why to Miss RightMichael J Harvey, Lisa A Prosser, Mark L Messonnier, et al.
Plos One|March 3, 2023
Best-worst scaling preferences among patients with well-controlled epilepsy: Pilot resultsSamuel W Terman, Hélène E Aschmann, David W Hutton, et al.
Pageof 11

Showing results (21-30 of 103) with videos related to

Sort By:
Pageof 11
JAMA Ophthalmology|February 2, 2023
Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular EdemaDavid W Hutton, Adam R Glassman, Danni Liu, et al.
Annals of Internal Medicine|December 17, 2009
Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemicNayer Khazeni, David W Hutton, Alan M Garber, et al.
Vaccine|April 24, 2019
Are community health workers cost-effective for childhood vaccination in India?Deepti Bettampadi, Matthew L Boulton, Laura E Power, et al.
Annals of Internal Medicine|October 3, 2007
Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis BDavid W Hutton, Daniel Tan, Samuel K So, et al.
Gastroenterology|October 28, 2017
Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care ProvidersThilo Rattay, Ian P Dumont, Hauke S Heinzow, et al.
The American Journal of Gastroenterology|June 13, 2020
Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and HarmsNeehar D Parikh, Amit G Singal, David W Hutton, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 1, 2011
Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?Jeffrey K Belkora, David W Hutton, Dan H Moore, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|June 16, 2009
Are patients getting the "gist" in risk communication? Patient understanding of prognosis in breast cancer treatmentDavid W Hutton, Jeffrey K Belkora, Ross D Shachter, et al.
Plos One|June 23, 2016
Hitting the Optimal Vaccination Percentage and the Risks of Error: Why to Miss RightMichael J Harvey, Lisa A Prosser, Mark L Messonnier, et al.
Plos One|March 3, 2023
Best-worst scaling preferences among patients with well-controlled epilepsy: Pilot resultsSamuel W Terman, Hélène E Aschmann, David W Hutton, et al.
Pageof 11